Innovative Product Packaging
Pharmaceutical packaging and our on-going drive for patient safety
Wockhardt UK’s safer packaging designs help to enhance patient safety compared to our older packaging style
The drive to improve patient safety is vitally important to the NHS and is supported by the National Patient Safety Agency (NPSA).
With this in mind - over recent years - we have enhanced the packaging design of our generics product range, based on extensive research with our customers and in collaboration with the NPSA.
The key safety enhancements to our packaging include:
- Clearer font style and larger font sizes
- Carefully chosen colours to differentiate between product ranges and strengths, as recommended in the NPSA Guidelines.
- Route of administration (the way the medication is taken), clearly displayed on the front of the pack
- Duplication on the labels of the actual products where applicable.
Wockhardt UK was the first pharmaceutical company in the UK to use “Tall Man” lettering on packaging. It was initially introduced on our cephalosporin injection range and was then also applied to our other look-alike and sound-alike products too.
Tall Man lettering involves highlighting part of the drug's name on the packaging and also the labelling where applicable. For example, cefotaxime and ceftazidime are written as cefotaxime and ceftazidime, which helps to distinguish between look-alike and sound-alike product names, by clearly identifying and highlighting the different parts of the product names which may cause confusion.
The aim of using Tall Man lettering is to reduce the risk of mis-selection.
The MHRA have now issued guidance stating that the packaging and labelling for all generic cephalosporins - from all pharmaceutical companies - should include the Tall Man lettering.
At Wockhardt UK, we are constantly looking at new and innovative ways to improve our product packaging, so if you do have any suggestions, then please do not hesitate to contact us. We value your opinion and all reasonable suggestions will be considered.